Drug Trial Radar · NCT05969223
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
Last checked: Nov 20, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
214
Actual
Start
Aug 10, 2023
Primary completion
Jan 22, 2025
Study completion Nov 28, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Approximately 200 participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis will be enrolled across approximately 45 sites globally. The study will be broken up into 2 studies by disease location, participants with moderate to severe genital psoriasis (Study-G) and moderate to severe scalp psoriasis (Study-S). In both studies participants will receive subcutaneous (SC) injections of risankizumab during the 52 week treatment period, or SC injections of placebo risankizumab during the 16 week treatment period followed by SC injections of risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Genital Psoriasis
- Scalp Psoriasis
Interventions
RisankizumabDrug
Subcutaneous injection
Placebo for RisankizumabDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16Time frame: Week 16
- Study-S: Percentage of Participants With Achievement of Scalp Investigator Global Assessment (IGA) of 0 or 1 at Week 16Time frame: Week 16
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Medical Dermatology Specialists /ID# 262915
Phoenix, Arizona
Alliance Dermatology and Mohs Center /ID# 255846
Phoenix, Arizona
Banner University Medicine Dermatology /ID# 255845
Tucson, Arizona
Private Practice - Dr. Tooraj Raoof /ID# 255334
Encino, California
Dermatology Research Associates /ID# 255347
Los Angeles, California
Clinical Trials Research Institute /ID# 264555
Thousand Oaks, California
Florida Academic Dermatology Center /ID# 264065
Coral Gables, Florida
Skin Care Research - Hollywood /ID# 255394
Hollywood, Florida
GSI Clinical Research, LLC /ID# 255472
Margate, Florida
Skin and Cancer Associates, LLP /ID# 255506
Miami, Florida
Sullivan Dermatology /ID# 264067
Miami, Florida
Renstar Medical Research /ID# 255339
Ocala, Florida
Hamilton Research, LLC /ID# 255409
Alpharetta, Georgia
Treasure Valley Medical Research /ID# 255671
Boise, Idaho
DeNova Research /ID# 264063
Chicago, Illinois
Arlington Dermatology /ID# 255330
Rolling Meadows, Illinois
The Indiana Clinical Trials Center /ID# 255333
Plainfield, Indiana
Dermatology Partners of Leawood /ID# 263244
Leawood, Kansas
DermAssociates - Rockville /ID# 263252
Rockville, Maryland
Skin Specialists /ID# 262929
Omaha, Nebraska
Skin Cancer and Dermatology Institute (SCDI) /ID# 264570
Sparks, Nevada
Care Access - Hoboken /ID# 264066
Hoboken, New Jersey
Forest Hills Dermatology Group @ Union Turnpike /ID# 255346
Kew Gardens, New York
Schweiger Dermatology, P.C. /ID# 255336
New York, New York
Darst Dermatology /ID# 255848
Charlotte, North Carolina
Wright State Physicians Health Center /ID# 255395
Fairborn, Ohio
Apex Clinical Research Center /ID# 263432
Mayfield Heights, Ohio
Oregon Dermatology and Research Center /ID# 255670
Portland, Oregon
Oregon Medical Research Center /ID# 255332
Portland, Oregon
Studies in Dermatology LLC /ID# 262989
Cypress, Texas
Modern Research Associates /ID# 263234
Dallas, Texas
Center for Clinical Studies - Houston (Binz) /ID# 255396
Houston, Texas
U.S. Dermatology Partners Longview /ID# 266325
Longview, Texas
Progressive Clinical Research - San Antonio /ID# 263255
San Antonio, Texas
Center for Clinical Studies Webster TX /ID# 255518
Webster, Texas
Care Access - Danville /ID# 266300
Danville, Virginia
Center for Excellence in Dermatology /ID# 264647
Kennewick, Washington
North Sound Dermatology /ID# 264565
Mill Creek, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.